share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  05/24 01:18
牛牛AI助理已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has reported the cessation of 5 million options due to the lapse of conditional rights. The options, identified by the ASX security code ATHAAE and expiring on November 29, 2026, with an exercise price of $0.0375, ceased on May 7, 2024, because the conditions for their exercise were not met or became incapable of being satisfied. The cessation was attributed to employee resignation. Following this event, the company's issued capital includes over 5.2 billion ordinary fully paid shares and a variety of options with different expiration dates and exercise prices. The announcement was made on May 21, 2024, and is in accordance with the rules of the Securities Exchange Act of 1934, as Alterity Therapeutics is a foreign private issuer registered with the SEC.
Alterity Therapeutics Limited, a development stage enterprise, has reported the cessation of 5 million options due to the lapse of conditional rights. The options, identified by the ASX security code ATHAAE and expiring on November 29, 2026, with an exercise price of $0.0375, ceased on May 7, 2024, because the conditions for their exercise were not met or became incapable of being satisfied. The cessation was attributed to employee resignation. Following this event, the company's issued capital includes over 5.2 billion ordinary fully paid shares and a variety of options with different expiration dates and exercise prices. The announcement was made on May 21, 2024, and is in accordance with the rules of the Securities Exchange Act of 1934, as Alterity Therapeutics is a foreign private issuer registered with the SEC.
處於開發階段的企業Alterity Therapeutics Limited報告稱，由於有條件權利的失效，已停止500萬份期權。這些期權由澳大利亞證券交易所安全代碼ATHAAE確定，將於2026年11月29日到期，行使價爲0.0375美元，由於行使條件未得到滿足或無法滿足，於2024年5月7日終止。停職歸因於員工辭職。此次活動之後，該公司的已發行資本包括超過52億股全額支付的普通股以及具有不同到期日和行使價的各種期權。該公告於2024年5月21日發佈，符合1934年《證券交易法》的規定，因爲Alterity Therapeutics是一家在美國證券交易委員會註冊的外國私人發行人。
處於開發階段的企業Alterity Therapeutics Limited報告稱，由於有條件權利的失效，已停止500萬份期權。這些期權由澳大利亞證券交易所安全代碼ATHAAE確定，將於2026年11月29日到期，行使價爲0.0375美元，由於行使條件未得到滿足或無法滿足，於2024年5月7日終止。停職歸因於員工辭職。此次活動之後，該公司的已發行資本包括超過52億股全額支付的普通股以及具有不同到期日和行使價的各種期權。該公告於2024年5月21日發佈，符合1934年《證券交易法》的規定，因爲Alterity Therapeutics是一家在美國證券交易委員會註冊的外國私人發行人。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。